PF-114

a tyrosine kinase inhibitor; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Philadelphia Chromosome 05/01/2015 - "PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation."
2.	Leukemia 05/01/2015 - "Our work supports clinical evaluation of PF-114 for the treatment of resistant Ph+ leukemia. " 05/01/2015 - "PF-114 is a novel TKI developed with the specifications of (i) targeting T315I and other resistance mutations in BCR/ABL; (ii) achieving a high selectivity to improve safety; and (iii) overcoming nonmutational resistance in Ph+ leukemias. " 05/01/2015 - "PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation." 05/01/2015 - "In BCR/ABL- or BCR/ABL-T315I-driven murine leukemia as well as in xenograft models of primary Ph+ leukemia harboring the T315I, PF-114 significantly prolonged survival to a similar extent as ponatinib. "

1.	ponatinib